#### Edgar Filing: Davidson David - Form 4

Davidson D Form 4	avid										
October 04,	2017										
								OMB APPROVAL			
Washington, D.C. 20549								OMB Number:	3235-0287		
Check this box if no longer										January 31, 2005	
subject to STATEMENT OF CHANG					GES IN BENEFICIAL OWNERSHIP SECURITIES				Estimated average burden hours per response 0.		
Form 5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).											
(Print or Type	Responses)										
Davidson David Symbol				ssuer Name <b>and</b> Ticker or Trading ool bird bio, Inc. [BLUE]				5. Relationship of Reporting Person(s) to Issuer			
(Last)					-	-		(Check	ek all applicable)		
(Month/				ate of Earliest Transaction nth/Day/Year) )2/2017				Director 10% Owner X_ Officer (give title Other (specify below) below) Chief Medical Officer			
				Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)     (State)     (Zip)     Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution 1 any	ed 3. 4. Securitie			ities A osed of	Acquired (A) 5. Amount of of (D) Securities		6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	7 Amount	(A) or t (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	10/02/2017			М	4,000	A	\$ 5.5004	19,977	D		
Common Stock	10/02/2017			S <u>(1)</u>	1,341	D	\$ 130.37. (2)	<sup>3</sup> 18,636	D		
Common Stock	10/02/2017			S <u>(1)</u>	2,459	D	\$ 131.7524 (3)	16,177	D		
Common Stock	10/02/2017			S <u>(1)</u>	200	D	\$ 132.2	15,977	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)				8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 5.5004	10/02/2017		М	4,000	<u>(4)</u>	01/16/2023	Common Stock	4,000	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE, MA 02142			Chief Medical Officer				
Signatures							
/s/Jason F. Cole, Attorney-in-Fact	1	0/04/2017					

Date

\*\*Signature of Reporting Person

of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.

The range of prices for the transaction reported on this line was \$130.00 to \$130.75. The average weighted price was \$130.3730. The

(2) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

#### Edgar Filing: Davidson David - Form 4

The range of prices for the transaction reported on this line was \$131.05 to \$132.00. The average weighted price was \$131.7524. The(3) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(4) This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.